Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Book Volume: 25

Pages Range: e76-e85

Journal Issue: 3

DOI: 10.1016/j.bbmt.2018.12.068

Abstract

On August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present, ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring, and disease assessments. To address these issues experts representing the American Society for Blood and Marrow Transplant, the European Society for Blood and Marrow Transplantation, the International Society of Cell and Gene Therapy, and the Foundation for the Accreditation of Cellular Therapy formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Involved external institutions

University of Texas Southwestern Medical Center (UT Southwestern) United States (USA) (US) Penn Medicine United States (USA) (US) University of Washington United States (USA) (US) King Faisal Specialist Hospital & Research Centre Saudi Arabia (SA) The Ohio State University Wexner Medical Center (OSUMC) United States (USA) (US) Washington University in St. Louis United States (USA) (US) National Cancer Institute (NCI) United States (USA) (US) University of Pennsylvania United States (USA) (US) Memorial Sloan Kettering Cancer Center United States (USA) (US) Mayo Clinic United States (USA) (US) Sorbonne Université France (FR) Vanderbilt University United States (USA) (US) Texas Children's Hospital United States (USA) (US) Children’s National Health System United States (USA) (US) Sylvester Comprehensive Cancer Center United States (USA) (US) Mayo Clinic in Arizona United States (USA) (US) Aix-Marseille University / Aix-Marseille Université France (FR) Universitätsklinikum Würzburg Germany (DE) George Washington University (GWU) United States (USA) (US) University of Minnesota (UMN) United States (USA) (US) Ospedale San Raffaele (früher: Centro San Raffaele del Monte Tabor Foundation) Italy (IT) University of Texas MD Anderson Cancer Center United States (USA) (US) Tel Aviv University Israel (IL) H. Lee Moffitt Cancer Center & Research Institute United States (USA) (US) Mayo Clinic Hospital United States (USA) (US) King’s College London United Kingdom (GB) American University of Beirut Medical Center (AUBMC) Lebanon (LB) Stanford University United States (USA) (US)

How to cite

APA:

Kansagra, A.J., Frey, N.V., Bar, M., Laetsch, T.W., Carpenter, P.A., Savani, B.N.,... Hashmi, S.K. (2019). Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 25(3), e76-e85. https://doi.org/10.1016/j.bbmt.2018.12.068

MLA:

Kansagra, Ankit J., et al. "Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation." Biology of Blood and Marrow Transplantation 25.3 (2019): e76-e85.

BibTeX: Download